# Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma

> **NCT06124001** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **CNBG-Virogin Biotech (Shanghai) Ltd.** · enrollment: 36 (estimated)

## Conditions studied

- Primary Hepatocellular Carcinoma

## Interventions

- **DRUG:** Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
- **DRUG:** camrelizumab for Injection

## Key facts

- **NCT ID:** NCT06124001
- **Lead sponsor:** CNBG-Virogin Biotech (Shanghai) Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-11-30
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2023-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06124001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06124001, "Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06124001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*